Average Price Target: $10.13
▲ +362.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Windtree Therapeutics in the last 3 months. The average price target is $10.13, with a high forecast of $12.25 and a low forecast of $8.00. The average price target represents a 362.33% upside from the last price of $2.19.
The current consensus among 2 polled investment analysts is to buy stock in Windtree Therapeutics.
Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.